Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus LASIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus LASIX.
ETHACRYNATE SODIUM vs LASIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Category C
Category C
Loop Diuretic
Loop Diuretic